A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
Yu ZhangSaisai LiYing WangYang LuYingxi XuQing RaoHuijun WangHaiyan XingZheng TianKejing TangLulu LvMin WangJian-Xiang WangPublished in: Experimental hematology & oncology (2022)
Chinese Clinical Trial Registry (ChiCTR): ChiCTR1900025419, Supplementarily registered 26 August, 2019.